Ball-and-stick model of the 5-APB molecule
Clinical data
ATC code none
Legal status
Legal status
Synonyms 1-Benzofuran-5-ylpropan-2-amine
CAS Number 286834-81-9 N
PubChem (CID) 9837232
ChemSpider 8012953 YesY
Chemical and physical data
Formula C11H13NO
Molar mass 175.23 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

5-APB (abbreviation of "5-(2-aminopropyl)benzofuran"; see infobox for the correct IUPAC name) is an empathogenic psychoactive compound of the substituted benzofuran, substituted amphetamine and substituted phenethylamine classes. 5-APB and other compounds are sometimes informally called "Benzofury".

5-APB is commonly found as the succinate and hydrochloride salt. The hydrochloride salt is 10% more potent by mass and doses should be adjusted accordingly.

5-APB has been sold as a designer drug since 2010.[1]


5-APB is a serotonin–norepinephrine–dopamine reuptake inhibitor with Ki(NET)=180 nmol/L, Ki(DAT)=265 nmol/L and Ki(SERT)=811 nmol/L.[2] It is also a serotonin–norepinephrine–dopamine releasing agent.[3] 5-APB is a potent agonist for the 5-HT2A and 5-HT2B receptors (Ki of 14 nmol/L at 5-HT2B with an efficacy of[2] 0.924). This agonism for 5-HT2B makes it likely that 5-APB would be cardiotoxic with long term use, as seen in other 5-HT2B agonists such as fenfluramine and MDMA. 5-APB is also an agonist of the 5-HT2C receptor.[4]


A forensic standard of 5-APB is available, and the compound has been posted on the Forendex website of potential drugs of abuse.[5] The US Department of Justice and DEA have also conducted studies concerning the detection of 5-APB.[6]


Users describe effects as euphoric. Largely, effects reported were similar to that of the drug MDA but not as strong. Recreational use of 5-APB has been associated with death in combination with other drugs.[7][8]


On March 5, 2014 the UK Home Office announced that 6-APB would be made a class B drug on 10 June 2014 alongside every other benzofuran entactogen and many structurally related drugs.[9]


  1. http://www.emcdda.europa.eu/publications/implementation-reports/2010 EMCDDA–Europol 2010 Annual Report on the implementation of Council Decision 2005/387/JHA
  2. 1 2 Iversen, L.; Gibbons, S.; Treble, R.; Setola, V.; Huang, X. P.; Roth, B. L. (2013). "Neurochemical profiles of some novel psychoactive substances". European Journal of Pharmacology. 700 (1-3). doi:10.1016/j.ejphar.2012.12.006. PMC 3582025Freely accessible. PMID 23261499.
  3. Rickli, A; Kopf, S; Hoener, MC; Liechti, ME (2015). "Pharmacological profile of novel psychoactive benzofurans". British Pharmacological Society. 172 (13). doi:10.1111/bph.13128. PMC 4500375Freely accessible. PMID 25765500.
  4. US patent 7045545, Karin Briner et al, "Aminoalkylbenzofurans as serotonin (5-HT(2c)) agonists", published 2000-01-19, issued 2006-16-03
  5. Southern Association of Forensic Scientists, http://forendex.southernforensic.org/index.php/detail/index/1135
  6. USDOJ/DEA, http://www.justice.gov/dea/pr/microgram-journals/2011/mj8-2_62-74.pdf
  7. "UCSD student dies of drug overdose after on-campus music festival". Los Angeles Times. August 20, 2014.
  8. "The effects of benzofury (5-APB) on the dopamine transporter and 5-HT2-dependent vasoconstriction in the rat". Prog Neuropsychopharmacol Biol Psychiatry. 48: 57–63. Jan 3, 2014. doi:10.1016/j.pnpbp.2013.08.013. PMID 24012617. 5-APB ... has been implicated in 10 recent drug-related deaths in the UK
  9. UK Home Office (2014-03-05). "The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014". UK Government. Retrieved 2014-03-11.
This article is issued from Wikipedia - version of the 9/19/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.